Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials

Peer Review reports

Original Submission
26 Jan 2018	Submitted	Original manuscript
7 May 2018	Reviewed	Reviewer Report - Keyue Ding
19 Jan 2019	Reviewed	Reviewer Report - Reviewer 2
28 Feb 2019	Author responded	Author comments - Martin Connock
Resubmission - Version 2
28 Feb 2019	Submitted	Manuscript version 2
19 Mar 2019	Author responded	Author comments - Martin Connock
Resubmission - Version 3
19 Mar 2019	Submitted	Manuscript version 3
Publishing
21 Mar 2019	Editorially accepted
25 Apr 2019	Article published	10.1186/s12885-019-5507-6

Back to article page